BACKGROUND: Extensive research has implicated inflammation as a necessary and causative factor in the development of peri-implant osteolysis, suggesting that such an inflammatory response is the sentinel event for the process. The potential to impact the clinical course of this condition is hampered by the lack of an effective medical therapy, as well as a limited ability for early detection prior to radiographically evident osteolysis. Advances in nanotechnology have allowed for the production of engineered water-soluble nanocarriers, which exploit changes in the microvascular architecture for selective distribution to inflamed tissues. Evaluation of the uptake of the nanocarriers in sites of inflammation has elucidated a novel mechanism of cellular uptake and retention of these particles. PURPOSE: The current review discusses the development of a novel, biocompatible, water-soluble nanocarrier utilizing copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA), conjugated to imaging and therapeutic agents for the detection and targeted treatment of inflammatory conditions. METHODS: We performed Medline searches for the terms "periprosthetic osteolysis," "murine osteolysis model," "HPMA osteolysis," and "HPMA inflammation." These searches identified 631, 306, 1, and 6 articles, respectively. These were then manually searched for articles relevant to the development of mouse models for inflammatory osteolysis and the use of HPMA copolymer technology in mouse models of inflammation. RESULTS: Promising results in a small animal model of osteolysis have demonstrated the capability for detection prior to the development of bone loss, and have highlighted the utility of nanocarriers for selective drug delivery to the affected tissues. CONCLUSIONS: Challenges to the clinical translation of HPMA nanocarriers in peri-implant osteolysis remain, and the future research directions necessary for human clinical application are reviewed.
BACKGROUND: Extensive research has implicated inflammation as a necessary and causative factor in the development of peri-implant osteolysis, suggesting that such an inflammatory response is the sentinel event for the process. The potential to impact the clinical course of this condition is hampered by the lack of an effective medical therapy, as well as a limited ability for early detection prior to radiographically evident osteolysis. Advances in nanotechnology have allowed for the production of engineered water-soluble nanocarriers, which exploit changes in the microvascular architecture for selective distribution to inflamed tissues. Evaluation of the uptake of the nanocarriers in sites of inflammation has elucidated a novel mechanism of cellular uptake and retention of these particles. PURPOSE: The current review discusses the development of a novel, biocompatible, water-soluble nanocarrier utilizing copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA), conjugated to imaging and therapeutic agents for the detection and targeted treatment of inflammatory conditions. METHODS: We performed Medline searches for the terms "periprosthetic osteolysis," "murineosteolysis model," "HPMAosteolysis," and "HPMAinflammation." These searches identified 631, 306, 1, and 6 articles, respectively. These were then manually searched for articles relevant to the development of mouse models for inflammatory osteolysis and the use of HPMA copolymer technology in mouse models of inflammation. RESULTS: Promising results in a small animal model of osteolysis have demonstrated the capability for detection prior to the development of bone loss, and have highlighted the utility of nanocarriers for selective drug delivery to the affected tissues. CONCLUSIONS: Challenges to the clinical translation of HPMA nanocarriers in peri-implant osteolysis remain, and the future research directions necessary for human clinical application are reviewed.
Authors: Neil Cobelli; Brian Scharf; Giovanna M Crisi; John Hardin; Laura Santambrogio Journal: Nat Rev Rheumatol Date: 2011-09-06 Impact factor: 20.543
Authors: Tim A Walde; Daniel E Weiland; Serena B Leung; Nobuto Kitamura; Christi J Sychterz; C Anderson Engh; Alexandra M Claus; Hollis G Potter; Charles A Engh Journal: Clin Orthop Relat Res Date: 2005-08 Impact factor: 4.176
Authors: Jon R Ward; Peter W West; Mark P Ariaans; Lisa C Parker; Sheila E Francis; David C Crossman; Ian Sabroe; Heather L Wilson Journal: J Biol Chem Date: 2010-05-21 Impact factor: 5.157
Authors: Panagiotis Koulouvaris; Khanh Ly; Lionel B Ivashkiv; Mathias P Bostrom; Bryan J Nestor; Thomas P Sculco; P Edward Purdue Journal: J Orthop Res Date: 2008-01 Impact factor: 3.494
Authors: Steven M Kurtz; Edmund Lau; Kevin Ong; Ke Zhao; Michael Kelly; Kevin J Bozic Journal: Clin Orthop Relat Res Date: 2009-04-10 Impact factor: 4.176
Authors: Ling-dong Quan; P Edward Purdue; Xin-ming Liu; Michael D Boska; Subodh M Lele; Geoffrey M Thiele; Ted R Mikuls; Huanyu Dou; Steven R Goldring; Dong Wang Journal: Arthritis Res Ther Date: 2010-09-13 Impact factor: 5.156
Authors: Xin Wei; Fei Li; Gang Zhao; Yashpal Singh Chhonker; Christine Averill; Josselyn Galdamez; P Edward Purdue; Xiaoyan Wang; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Yazen Alnouti; Dong Wang Journal: Mol Pharm Date: 2017-04-05 Impact factor: 4.939
Authors: Melissa N Zimel; Chloe B Horowitz; Vinagolu K Rajasekhar; Alexander B Christ; Xin Wei; Jianbo Wu; Paulina M Wojnarowicz; Dong Wang; Steven R Goldring; P Edward Purdue; John H Healey Journal: Mol Cancer Ther Date: 2017-08-22 Impact factor: 6.261
Authors: Brittany M Wilson; Meghan M Moran; Matthew J Meagher; Ryan D Ross; Maleeha Mashiatulla; Amarjit S Virdi; Dale R Sumner Journal: J Orthop Res Date: 2019-12-25 Impact factor: 3.494
Authors: Adrese M Kandahari; Xinlin Yang; Kevin A Laroche; Abhijit S Dighe; Dongfeng Pan; Quanjun Cui Journal: Bone Res Date: 2016-07-12 Impact factor: 13.567